← Back to Clinical Trials
Recruiting NCT06830980

NCT06830980 Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06830980
Status Recruiting
Phase
Sponsor Gopalkumar Rakesh
Condition Methamphetamine Use Disorders
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-03-11
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
intermittent theta burst stimulation (iTBS)continuous theta burst stimulation (cTBS)Sham TMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-03-11 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

Eligibility Criteria

Inclusion Criteria: * Adults in the age group 18-65 years * Able to read and understand English * Able to provide informed consent * Diagnosed with HIV * History of current or previous Methamphetamine Use Disorder * Endorse craving for methamphetamine * Demonstrate an attentional bias for methamphetamine Exclusion Criteria: * Traumatic brain injury * h/o seizure disorder * h/o or current diagnosis of schizophrenia * intracranial metal shrapnel * previous adverse effects with TMS * sub-threshold consistency while performing behavioral tasks * lack of attentional bias to methamphetamine cues * a positive pregnancy test for female participants * abnormal brain MRI

Contact & Investigator

Central Contact

Patricia Garth, CRC

✉ psych_research@uky.edu, annette.garth@uky.edu

📞 859-382-7611

Principal Investigator

Gopalkumar Rakesh, MD

PRINCIPAL INVESTIGATOR

University of Kentucky

Frequently Asked Questions

Who can join the NCT06830980 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Methamphetamine Use Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06830980 currently recruiting?

Yes, NCT06830980 is actively recruiting participants. Contact the research team at psych_research@uky.edu, annette.garth@uky.edu for enrollment information.

Where is the NCT06830980 trial being conducted?

This trial is being conducted at Lexington, United States.

Who is sponsoring the NCT06830980 clinical trial?

NCT06830980 is sponsored by Gopalkumar Rakesh. The principal investigator is Gopalkumar Rakesh, MD at University of Kentucky. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology